Sendero Wealth Management LLC Has $4.54 Million Stake in DexCom, Inc. $DXCM

Sendero Wealth Management LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 85.6% during the third quarter, Holdings Channel.com reports. The institutional investor owned 67,423 shares of the medical device company’s stock after acquiring an additional 31,094 shares during the quarter. Sendero Wealth Management LLC’s holdings in DexCom were worth $4,537,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Norges Bank acquired a new stake in DexCom during the 2nd quarter worth approximately $453,279,000. Groupama Asset Managment grew its stake in DexCom by 79,043.1% during the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after buying an additional 4,011,438 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of DexCom by 106.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after acquiring an additional 3,410,858 shares in the last quarter. Marshall Wace LLP raised its position in DexCom by 260.7% during the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after purchasing an additional 2,762,504 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after buying an additional 1,868,241 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In other DexCom news, Director Richard Alexander Collins sold 3,948 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the completion of the transaction, the director owned 37,994 shares in the company, valued at approximately $2,096,128.98. This trade represents a 9.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director owned 27,031 shares in the company, valued at $1,569,690.17. This trade represents a 3.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,866 shares of company stock valued at $448,177 over the last ninety days. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Robert W. Baird set a $82.00 price objective on shares of DexCom in a research report on Friday, October 31st. Canaccord Genuity Group set a $99.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Friday, October 31st. Leerink Partners reissued an “outperform” rating and set a $92.00 price objective on shares of DexCom in a report on Tuesday. Wells Fargo & Company set a $93.00 price objective on DexCom and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, Truist Financial reiterated a “buy” rating and issued a $82.00 target price (down from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.61.

DexCom Stock Performance

NASDAQ DXCM opened at $65.75 on Thursday. The company has a market capitalization of $25.64 billion, a price-to-earnings ratio of 36.53, a PEG ratio of 1.42 and a beta of 1.51. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The stock has a fifty day simple moving average of $63.96 and a 200 day simple moving average of $74.03. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.45 EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.